In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:CDC PrEP guideline 2021 updates for oral PrEPThe ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infectionA review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP1-year follow-up after unblinding for HPTN 083 and 084LA CAB for PrEP: monitoring and safetyStopping LA CAB for PrEPPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:https://bit.ly/3Gh9AKG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related